These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 20422500)

  • 21. Inflammation mediated down-regulation of hepatobiliary transporters contributes to intrahepatic cholestasis and liver damage in murine biliary atresia.
    Yang H; Plösch T; Lisman T; Gouw AS; Porte RJ; Verkade HJ; Hulscher JB
    Pediatr Res; 2009 Oct; 66(4):380-5. PubMed ID: 19581828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epistane, an anabolic steroid used for recreational purposes, causes cholestasis with elevated levels of cholic acid conjugates, by upregulating bile acid synthesis (CYP8B1) and cross-talking with nuclear receptors in human hepatocytes.
    Petrov PD; Fernández-Murga L; Conde I; Martínez-Sena T; Guzmán C; Castell JV; Jover R
    Arch Toxicol; 2020 Feb; 94(2):589-607. PubMed ID: 31894354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response.
    Cai SY; Ouyang X; Chen Y; Soroka CJ; Wang J; Mennone A; Wang Y; Mehal WZ; Jain D; Boyer JL
    JCI Insight; 2017 Mar; 2(5):e90780. PubMed ID: 28289714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear receptors as therapeutic targets in cholestatic liver diseases.
    Zollner G; Trauner M
    Br J Pharmacol; 2009 Jan; 156(1):7-27. PubMed ID: 19133988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bile acid interactions with cholangiocytes.
    Xia X; Francis H; Glaser S; Alpini G; LeSage G
    World J Gastroenterol; 2006 Jun; 12(22):3553-63. PubMed ID: 16773712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations.
    Zollner G; Marschall HU; Wagner M; Trauner M
    Mol Pharm; 2006; 3(3):231-51. PubMed ID: 16749856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration.
    Geier A; Wagner M; Dietrich CG; Trauner M
    Biochim Biophys Acta; 2007 Mar; 1773(3):283-308. PubMed ID: 17291602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
    Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
    Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic cholestasis, causes and consequences for hepatobiliary transport.
    Jansen PL; Sturm E
    Liver Int; 2003 Oct; 23(5):315-22. PubMed ID: 14708891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TGR5 signaling mitigates parenteral nutrition-associated liver disease.
    Willis KA; Gomes CK; Rao P; Micic D; Moran ER; Stephenson E; Puchowicz M; Al Abdallah Q; Mims TS; Gosain A; Yin D; Talati AJ; Chang EB; Han JC; Pierre JF
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G322-G335. PubMed ID: 31905022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible impairment of neonatal hepatobiliary function by maternal cholestasis.
    Monte MJ; Morales AI; Arevalo M; Alvaro I; Macias RI; Marin JJ
    Hepatology; 1996 May; 23(5):1208-17. PubMed ID: 8621155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholestasis-induced bile acid elevates estrogen level via farnesoid X receptor-mediated suppression of the estrogen sulfotransferase SULT1E1.
    Liu X; Xue R; Yang C; Gu J; Chen S; Zhang S
    J Biol Chem; 2018 Aug; 293(33):12759-12769. PubMed ID: 29929982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.
    Zollner G; Fickert P; Zenz R; Fuchsbichler A; Stumptner C; Kenner L; Ferenci P; Stauber RE; Krejs GJ; Denk H; Zatloukal K; Trauner M
    Hepatology; 2001 Mar; 33(3):633-46. PubMed ID: 11230744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity.
    Chen F; Ananthanarayanan M; Emre S; Neimark E; Bull LN; Knisely AS; Strautnieks SS; Thompson RJ; Magid MS; Gordon R; Balasubramanian N; Suchy FJ; Shneider BL
    Gastroenterology; 2004 Mar; 126(3):756-64. PubMed ID: 14988830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis.
    Recknagel P; Gonnert FA; Westermann M; Lambeck S; Lupp A; Rudiger A; Dyson A; Carré JE; Kortgen A; Krafft C; Popp J; Sponholz C; Fuhrmann V; Hilger I; Claus RA; Riedemann NC; Wetzker R; Singer M; Trauner M; Bauer M
    PLoS Med; 2012; 9(11):e1001338. PubMed ID: 23152722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis.
    Mulder J; Karpen SJ; Tietge UJ; Kuipers F
    Front Biosci (Landmark Ed); 2009 Jan; 14(7):2599-630. PubMed ID: 19273222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatobiliary transporters and drug-induced cholestasis.
    Pauli-Magnus C; Meier PJ
    Hepatology; 2006 Oct; 44(4):778-87. PubMed ID: 17006912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immaturity of the biliary excretory system predisposes neonates to intrahepatic cholestasis.
    Abernathy CO; Utili R; Zimmerman HJ
    Med Hypotheses; 1979 Jun; 5(6):641-7. PubMed ID: 114737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic utility of hepatobiliary scintigraphy with 99mTc-DISIDA in neonatal cholestasis.
    Spivak W; Sarkar S; Winter D; Glassman M; Donlon E; Tucker KJ
    J Pediatr; 1987 Jun; 110(6):855-61. PubMed ID: 3585600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-naphthylisothiocyanate impairs bile acid homeostasis through AMPK-FXR pathways in rat primary hepatocytes.
    Li X; Liu R; Yu L; Yuan Z; Sun R; Yang H; Zhang L; Jiang Z
    Toxicology; 2016 Aug; 370():106-115. PubMed ID: 27702592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.